+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 37 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of targeted treatments, with or without the immune therapy drug atezolizumab, in women with recurrent or persistent endometrial cancer. This Phase IBII study uses genetic testing of tumor samples to assign participants to different groups based on specific tumor markers. The study aims to better understand how these targeted agents work in combination with or without immunotherapy and to identify the best treatment options for specific tumor profiles. Participants will first provide tumor tissue for genomic testing using the FoundationOne companion diagnostic. Based on the tumors genetic features, participants will be placed into specific study groups receiving targeted drugs alone or combined with atezolizumab. Treatments include various intravenous and oral drugs administered in cycles of 21 or 28 days. Each group enrolls about 20 to 24 participants and can be closed or expanded depending on results. The study also allows for additional groups to be added over time. During the study, participants will receive regular treatments and be monitored for tumor response, survival, and disease progression over several months. Researchers will assess overall response rates and the duration participants remain free from disease progression. Safety and side effects will also be closely monitored. Participants may have tumor scans, blood tests, and other evaluations to track the study drugs effects. The total follow-up period for outcomes like survival is up to 48 months, ensuring long-term observation of treatment impact.

Age: 18Years +FEMALEPhase 1Phase 2
21 locations
A

Actively Recruiting

Researchers are investigating whether Viv, a consumer-grade dietary supplement made from Magnolia officinalis bark extract, affects immune activity markers in adults with psoriasis. This clinical trial compares Viv to a placebo to understand its impact on inflammation-related proteins. Participants have stable psoriasis confirmed by a dermatologist and may have related conditions like psoriatic arthritis if not requiring systemic treatments. Participants will be randomly assigned to take either Viv, containing 200 mg of Magnolia officinalis bark extract, or a placebo daily for three months. The study is triple-blinded, meaning neither the participants nor researchers know who receives which treatment. Participants will use the supplement at home and collect blood samples themselves at the start, after one month, and after three months using provided kits. During the study, participants will complete electronic questionnaires about their psoriasis symptoms and quality of life at the beginning, one month, and three months. Researchers will analyze blood samples to measure changes in inflammatory proteins and immune cells over time. The primary outcome is the change in plasma Beta defensin 2 levels after 12 weeks. The total study period for participants is three months, with ongoing safety and adherence monitored remotely.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.

Age: 18Years +All GendersPhase 2Phase 3
378 locations
E

Actively Recruiting

Researchers are investigating the safety and effectiveness of a new device called the Alleviant ALV1 System, designed to create an interatrial shunt for patients with heart failure and reduced ejection fraction HFrEF. This prospective, randomized, double-blind, sham-controlled trial involves multiple centers and aims to compare the outcomes of patients receiving this device to those undergoing a sham procedure. The study focuses on those with heart failure who have a left ventricular ejection fraction of 40% or less and are classified as NYHA class II, III, or ambulatory IV. Participants are randomly assigned to one of two groups. The treatment group undergoes cardiac imaging, femoral vein access, and receives the Alleviant ALV1 System device procedure to create the interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement but does not receive the device. The study uses a crossover design, allowing comparison between the treatment and sham procedures under double-blind conditions. Throughout the study, participants will be monitored for safety and efficacy, with cardiac imaging used to assess outcomes. The primary outcome is a composite endpoint measured at 12 months, which evaluates the overall impact of the device on heart failure. The trial is sponsored by Alleviant Medical, Inc. and will continue until December 2028. Participants can expect regular assessments and follow-up visits during the study period.

Age: 18Years +All GendersPhase Not Applicable
70 locations
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
N

Actively Recruiting

Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.

All AgesAll Genders
630 locations
C

Actively Recruiting

Researchers are studying how to best monitor pancreatic cysts and identify biomarkers that may signal the risk of these cysts developing into pancreatic cancer. The study compares two different monitoring approaches with varying frequencies, aiming to learn which method and biomarkers help improve patient outcomes. This observational study focuses on adults aged 50 to 75 who have pancreatic cysts detected by imaging. Participants undergo either low-intensity or high-intensity surveillance programs. The low-intensity group receives MRI, CT, or endoscopic ultrasound EUS scans initially and at intervals up to every two years depending on findings. The high-intensity group has more frequent imaging based on cyst size, including regular MRI, CT, and EUS scans. Blood samples, biopsies, and fine-needle aspirations may also be collected as needed. The study follows patients for 5 years from enrollment. During the trial, participants have regular imaging tests such as MRI, CT, and EUS, along with blood sample collections to assess biomarkers related to cyst changes. Researchers monitor clinical outcomes including the development of worrisome or high-risk features, quality of life, anxiety, financial distress, and healthcare costs. The study also tracks adherence to surveillance and surgical outcomes. Follow-up continues for 5 years to capture long-term results and identify factors linked to pancreatic cyst progression.

Age: 50Years - 75YearsAll Genders
429 locations
R

Actively Recruiting

Researchers are evaluating the outcomes of different coronary artery bypass grafting techniques in women with heart disease. The trial compares multiple arterial grafting MAG to single arterial grafting SAG to see if using multiple arterial grafts improves major heart and brain-related events and quality of life. This international randomized clinical trial includes 2,300 women to assess differences in survival, stroke, heart attacks, repeat surgeries, and hospital readmissions, as well as physical and mental health. Participants will be randomly assigned to one of two groups. One group receives a single arterial graft using the left internal thoracic artery plus additional venous grafts. The other group receives multiple arterial grafts, including the left internal thoracic artery and at least one other arterial graft such as the right internal thoracic artery or radial artery, with possible additional arterial grafts. The study uses the infrastructure of an existing trial and follows patients for at least 2.5 years after surgery. During the study, researchers collect data on major adverse cardiac and cerebrovascular events, along with quality of life measured by general and disease-specific questionnaires. Physical and mental health symptoms are also assessed. Follow-up includes tracking deaths, strokes, heart attacks, repeat procedures, and hospital stays. The trial aims to provide detailed information on outcomes and quality of life in women undergoing coronary bypass surgery over a long-term period.

Age: 18Years +FEMALEPhase Not Applicable
146 locations
E

Actively Recruiting

Researchers are evaluating if active surveillance combined with hormonal therapy can effectively manage Ductal Carcinoma In Situ DCIS, an early stage of breast cancer. This Phase 2 trial aims to determine whether new endocrine treatments can increase the number of patients suitable for long-term active surveillance, potentially reducing the need for surgery and radiation that can have significant health effects. Participants will be randomly assigned to receive one of several hormonal therapies standard or low-dose tamoxifen, aromatase inhibitors exemestane, letrozole, anastrozole, or investigational drugs including Testosterone plus Anastrazole pellets, Elacestrant, or Z-endoxifen capsules. Treatments may last up to 36 months or 5 years depending on the therapy. Participants will have MRI evaluations at baseline, 3 months, and 6 months, then mammograms and MRIs alternating every 6 months. If evaluations suggest surgery is needed, participants will stop the study treatment and undergo surgery. During the trial, participants will provide blood samples to assess immune status, saliva samples for genetic testing, and tissue or slides from any surgery done as part of their usual care. Follow-up will continue annually for 10 years. Researchers will monitor adherence, lesion changes via imaging, and quality of life measures. The primary outcome is the number of patients remaining on active surveillance at 7 months, with other outcomes including risk assessment and progression over several years.

Age: 18Years +FEMALEPhase 2
30 locations

1-10 of 37

1